AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8947785 — intervention group
Group type: COMPARATOR
Intervention: Passive stimulation (mouth-breathing with stimuli delivered asynchronously)
Number of subjects: 12
Study 1750602 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oral famotidine
Number of subjects: 32
Study 1750602 — intervention group
Group type: COMPARATOR
Intervention: Double-dose oral ranitidine
Number of subjects: 32
Study 7044932 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 14
Study 7044932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30954641 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 55
Study 27913991 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free tafluprost
Number of subjects: 43
Study 27913991 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free dorzolamide/timolol fixed combination (triple PF regimen)
Number of subjects: 43
Study 27913991 — intervention group
Group type: COMPARATOR
Intervention: Preserved latanoprost
Number of subjects: 43
Study 25766854 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care monitoring (n=55)
Number of subjects: 103
Study 25766854 — intervention group
Group type: COMPARATOR
Intervention: Usual monitoring routines (n=48)
Number of subjects: 103
Study 25766854 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care monitoring
Number of subjects: 103
Study 23799935 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab + Specific Immunotherapy (SIT)
Number of subjects: 140
Study 23799935 — intervention group
Group type: COMPARATOR
Intervention: Specific Immunotherapy (SIT) + Placebo
Number of subjects: 140
Study 23799935 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab + SIT
Number of subjects: 140
Study 23799935 — intervention group
Group type: COMPARATOR
Intervention: SIT + Placebo
Number of subjects: 140
Study 21868795 — intervention group
Group type: EXPERIMENTAL
Intervention: DermaStream system (treatment group)
Number of subjects: 15
Study 21868795 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional methods)
Number of subjects: 15
Study 19195259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse low-intensity electromagnetic field (PLIMF) therapy, induction of 10 mT, frequency of 25 Hz, duration of 30 min, started in the 7th week after injury and lasted for 4 weeks.
Number of subjects: 29
Study 19195259 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PLIMF therapy), only exercise and range of motion therapy.
Number of subjects: 29
Study 19195259 — intervention group
Group type: EXPERIMENTAL
Intervention: PLIMF therapy in the experimental group.
Number of subjects: 29
Study 16923452 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl (3.75 g/day for 6 weeks)
Number of subjects: 48
Study 16923452 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl
Number of subjects: 48
Study 16923452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15453925 — intervention group
Group type: EXPERIMENTAL
Intervention: CVPP plus involved-field radiotherapy (IFRT) in phase 1 (1968-1985)
Number of subjects: 1254
Study 15453925 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced CVPP plus IFRT in phase 2 (1986-1996)
Number of subjects: 1254
Study 15453925 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD plus IFRT in phase 3 (1997-2003)
Number of subjects: 1254
Study 15453925 — intervention group
Group type: EXPERIMENTAL
Intervention: CVPP plus IFRT in phase 1 for clinical stage III/IV
Number of subjects: 1254
Study 15453925 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced CVPP plus IFRT in phase 2 for clinical stage III/IV
Number of subjects: 1254
Study 15453925 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD plus IFRT in phase 3 for clinical stage III/IV
Number of subjects: 1254
Study 11305069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation-based stress reduction program (1.5 h each week for 7 weeks, plus daily home meditation practice)
Number of subjects: 89
Study 11305069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation-based stress reduction program
Number of subjects: 89
Study 9280254 — intervention group
Group type: EXPERIMENTAL
Intervention: Resovist (4 micromol Fe/kg)
Number of subjects: 36
Study 9280254 — intervention group
Group type: EXPERIMENTAL
Intervention: Resovist (8 micromol Fe/kg)
Number of subjects: 36
Study 9280254 — intervention group
Group type: EXPERIMENTAL
Intervention: Resovist (16 micromol Fe/kg)
Number of subjects: 36
Study 9280254 — intervention group
Group type: EXPERIMENTAL
Intervention: Resovist (all doses)
Number of subjects: 36
Study 7712677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion (8-hour initial infusion followed by 40-hour infusion)
Number of subjects: 200
Study 7712677 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after 8-hour lidocaine infusion)
Number of subjects: 200
Study 7712677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 200
Study 7712677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 7712677 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with initial ventricular fibrillation (not included in randomized study)
Number of subjects: 200
Study 2565329 — intervention group
Group type: EXPERIMENTAL
Intervention: NAD (nadolol, 80 mg/day)
Number of subjects: 8
Study 2565329 — intervention group
Group type: EXPERIMENTAL
Intervention: AT (atenolol, 100 mg/day)
Number of subjects: 8
Study 2565329 — intervention group
Group type: COMPARATOR
Intervention: PLAC (placebo)
Number of subjects: 8
Study 1009290 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought-disordered group
Number of subjects: 2
Study 1009290 — intervention group
Group type: COMPARATOR
Intervention: Non-thought-disordered group
Number of subjects: 2
Study 31833786 — intervention group
Group type: EXPERIMENTAL
Intervention: isCGM
Number of subjects: 20
Study 31757033 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GSPE (400 mg/day)
Number of subjects: 30
Study 31757033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31757033 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose GSPE (200 mg/day)
Number of subjects: 30
Study 26069290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 528
Study 26069290 — intervention group
Group type: COMPARATOR
Intervention: Placebo or Best Available Therapy
Number of subjects: 528
Study 26069290 — intervention group
Group type: COMPARATOR
Intervention: Crossover-adjusted Control
Number of subjects: 528
Study 23364015 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Beverages (DBs)
Number of subjects: 210
Study 23364015 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 210
Study 21875472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine 1000 mg
Number of subjects: 72
Study 21875472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine 2000 mg
Number of subjects: 72
Study 21875472 — intervention group
Group type: COMPARATOR
Intervention: Original intravesical chemotherapy
Number of subjects: 72
Study 21875472 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (combined groups A and B)
Number of subjects: 72
Study 17403597 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure to spider
Number of subjects: 0
Study 17403597 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal exposure to spider
Number of subjects: 0
Study 17403597 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulations of uncontrollability, unpredictability, and dangerousness
Number of subjects: 0
Study 17403597 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of spiders as uncontrollable, unpredictable, and dangerous
Number of subjects: 0
Study 16961291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 300 mg three times daily
Number of subjects: 68
Study 16961291 — intervention group
Group type: COMPARATOR
Intervention: Control group (10% glucose, Vitamin C, and Inosine)
Number of subjects: 68
Study 12965314 — intervention group
Group type: EXPERIMENTAL
Intervention: Preop‐TEA (8 mL of 0.25% bupivacaine plus fentanyl 50 microg in 2 mL administered preoperatively)
Number of subjects: 61
Study 12965314 — intervention group
Group type: COMPARATOR
Intervention: Postop‐TEA (no medication administered preoperatively and intraoperatively, postoperative analgesia maintained with patient‐controlled epidural analgesia with bupivacaine and fentanyl solution)
Number of subjects: 61
Study 10852444 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic clamp of 2.9 +/‐ 0.1 mmol/L after euglycemia (5.1 +/‐ 0.1 mmol/L) on day 1
Number of subjects: 15
Study 10852444 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycemia of 3.9, 3.3, and 2.9 +/‐ 0.1 mmol/L
Number of subjects: 15
Study 10852444 — intervention group
Group type: COMPARATOR
Intervention: Identical day 1 hypoglycemia of 3.9, 3.3, and 2.9 +/‐ 0.1 mmol/L
Number of subjects: 15
Study 8973428 — intervention group
Group type: COMPARATOR
Intervention: Nadolol alone
Number of subjects: 146
Study 8973428 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol plus isosorbide mononitrate
Number of subjects: 146
Study 1733145 — intervention group
Group type: EXPERIMENTAL
Intervention: JNIH-6 (two-component vaccine)
Number of subjects: 0
Study 1733145 — intervention group
Group type: EXPERIMENTAL
Intervention: JNIH-7 (monocomponent pertussis toxoid vaccine)
Number of subjects: 0
Study 1733145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6501058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular extraction
Number of subjects: 138
Study 6501058 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracapsular extraction
Number of subjects: 138
Study 6501058 — intervention group
Group type: EXPERIMENTAL
Intervention: On-the-table capsulotomy
Number of subjects: 138
Study 6501058 — intervention group
Group type: EXPERIMENTAL
Intervention: In-the-bag implantation without on-the-table capsulotomy
Number of subjects: 138
Study 6501058 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior-chamber-angle-fixated lenses
Number of subjects: 138
Study 6501058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 6501058 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 138
Study 31256014 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions, two times per week)
Number of subjects: 33
Study 31256014 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 33
Study 31256014 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 31303281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lusutrombopag (2 mg) in fasted state
Number of subjects: 48
Study 31303281 — intervention group
Group type: COMPARATOR
Intervention: Lusutrombopag (2 mg) in fed state
Number of subjects: 48
Study 31303281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lusutrombopag (0.75 mg) in fasted state
Number of subjects: 48
Study 31303281 — intervention group
Group type: COMPARATOR
Intervention: Lusutrombopag (0.75 mg) in fed state
Number of subjects: 48
Study 31303281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lusutrombopag (0.75 mg) with calcium carbonate in fasted state
Number of subjects: 48
Study 31303281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lusutrombopag (4 mg) in fasted state
Number of subjects: 48
Study 31303281 — intervention group
Group type: COMPARATOR
Intervention: Lusutrombopag (4 mg) in fed state
Number of subjects: 48
Study 29879254 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimni Cream by Hydropeptide
Number of subjects: 20
Study 29879254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27006014 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lateral femoral cutaneous nerve (LFCN) block with 8 ml of ropivacaine, 7.5 mg/ml (Group Ropivacaine)
Number of subjects: 100
Study 27006014 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 8 ml of saline (Group Placebo)
Number of subjects: 100
Study 24631129 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650 (20, 40, 60 or 80 μg/day)
Number of subjects: 0
Study 24631129 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650 (80 μg/day)
Number of subjects: 0
Study 24631129 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650 (not specified)
Number of subjects: 0
Study 22446171 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g daily for 8 weeks
Number of subjects: 20
Study 20851308 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional care for 6 months
Number of subjects: 241
Study 20851308 — intervention group
Group type: COMPARATOR
Intervention: Usual care of the health services
Number of subjects: 241
Study 17164313 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric banding surgery
Number of subjects: 33
Study 17164313 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 33
Study 16344227 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise myocardial perfusion single photon emission computed tomography (MPS)
Number of subjects: 1122
Study 16344227 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced ST depression (3 mm or greater)
Number of subjects: 1122
Study 16344227 — intervention group
Group type: EXPERIMENTAL
Intervention: % myo (percentage of myocardium involved with stress defects)
Number of subjects: 1122
Study 16344227 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced ST depression
Number of subjects: 1122
Study 12017402 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily at bedtime
Number of subjects: 681
Study 12017402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 681
Study 9823076 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite inlays cemented with All-Bond 2
Number of subjects: 50
Study 9823076 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite inlays cemented with Geristore
Number of subjects: 50
Study 7650122 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin and human menopausal gonadotrophin (HMG)
Number of subjects: 300
Study 7650122 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate and human menopausal gonadotrophin (HMG)
Number of subjects: 300
Study 1978496 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (low dose: 30-90 mg daily)
Number of subjects: 242
Study 1978496 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (middle dose: 120-240 mg daily)
Number of subjects: 242
Study 1978496 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (high dose: 300-600 mg daily)
Number of subjects: 242
Study 1978496 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (15-45 mg daily)
Number of subjects: 242
Study 1978496 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (all doses)
Number of subjects: 242
Study 580070 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CVP: cyclophosphamide, vincristine, and prednisone)
Number of subjects: 53
Study 580070 — intervention group
Group type: COMPARATOR
Intervention: Successive single agent chemotherapy (C-V-P: cyclophosphamide, vincristine, and prednisone used successively)
Number of subjects: 53
Study 580070 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CVP)
Number of subjects: 53
Study 580070 — intervention group
Group type: COMPARATOR
Intervention: Successive single agent chemotherapy (C-V-P)
Number of subjects: 53
Study 580070 — intervention group
Group type: COMPARATOR
Intervention: Neither regimen (CVP or C-V-P)
Number of subjects: 53
Study 31640632 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT plus standard medical care (SMC)
Number of subjects: 322
Study 31640632 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC) alone
Number of subjects: 322
Study 31640632 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT plus SMC
Number of subjects: 322
Study 31640632 — intervention group
Group type: COMPARATOR
Intervention: SMC alone
Number of subjects: 322
Study 29324911 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection with IORT (Group B)
Number of subjects: 56
Study 29324911 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection (Group A)
Number of subjects: 56
Study 25863654 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 822
Study 25863654 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 822
Study 23864097 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPEOX and bevacizumab
Number of subjects: 667
Study 23864097 — intervention group
Group type: COMPARATOR
Intervention: CAPEOX
Number of subjects: 667
Study 21770805 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading Center (RC) cup-to-disc ratio (CDR) assessment from stereoscopic photographs
Number of subjects: 479
Study 21770805 — intervention group
Group type: COMPARATOR
Intervention: Clinical estimation of CDR by ophthalmologists via dilated biomicroscopy
Number of subjects: 479
Study 19255389 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma coach intervention
Number of subjects: 306
Study 19255389 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306
Study 16646004 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 180
Study 16646004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 15508673 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU of vasopressin
Number of subjects: 1219
Study 15508673 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin followed by epinephrine
Number of subjects: 1219
Study 15508673 — intervention group
Group type: COMPARATOR
Intervention: 1 mg of epinephrine
Number of subjects: 1219
Study 15508673 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of vasopressin and epinephrine
Number of subjects: 1219
Study 15508673 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 1219
Study 11381289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (ACE inhibitor)
Number of subjects: 0
Study 11381289 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 0
Study 9231814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 5198
Study 9231814 — intervention group
Group type: COMPARATOR
Intervention: Active drug controls
Number of subjects: 5198
Study 9231814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine monotherapy
Number of subjects: 5198
Study 9231814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine in combination with another drug
Number of subjects: 5198
Study 9231814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine monotherapy vs combined therapy
Number of subjects: 5198
Study 8215633 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.14 mg/kg/day
Number of subjects: 14
Study 8215633 — intervention group
Group type: COMPARATOR
Intervention: Standard nutritional therapy (STD) providing approximately 50 kcal/kg/day and 2 g of protein/kg/day
Number of subjects: 14
Study 2882180 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid
Number of subjects: 70
Study 2882180 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 2882180 — intervention group
Group type: EXPERIMENTAL
Intervention: Sideroblastic anaemia patients
Number of subjects: 70
Study 29979912 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized multimodal treatment including manual therapy, patient education, stretching, resistance training, and neurodynamic interventions.
Number of subjects: 0
Study 30016335 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Number of subjects: 701
Study 26980460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin 5 mg/day
Number of subjects: 161
Study 26980460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin 10 mg/day
Number of subjects: 161
Study 26980460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin 20 mg/day
Number of subjects: 161
Study 26980460 — intervention group
Group type: COMPARATOR
Intervention: Control (existing antipsychotics)
Number of subjects: 161
Study 25651610 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 g/day banana for 12 weeks
Number of subjects: 45
Study 25651610 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 g/day banana for 12 weeks
Number of subjects: 45
Study 22522403 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 378
Study 22522403 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 378
Study 20712869 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged release melatonin (PRM) for 3 weeks
Number of subjects: 791
Study 20712869 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged release melatonin (PRM) for 26 weeks
Number of subjects: 791
Study 20712869 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks followed by placebo for 26 weeks
Number of subjects: 791
Study 20712869 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 791
Study 18674977 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week stretching program
Number of subjects: 40
Study 18674977 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained activity level for 8 weeks)
Number of subjects: 40
Study 15986032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-managed intervention including trial exit interview, trial feedback information leaflet, and telephone follow-up
Number of subjects: 117
Study 15986032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-managed intervention
Number of subjects: 117
Study 15986032 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 117
Study 12027266 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person survey regarding HBV knowledge, beliefs, and practices
Number of subjects: 320
Study 10333377 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term tryptophan (TRP) depletion
Number of subjects: 18
Study 10333377 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 18